Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma
December 10th 2023
Susan Bal, MD, discusses updated safety and efficacy data from a phase 1 study evaluating the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, including in patients with prior BCMA-directed therapy.